Chelsea Therapeutics (CHTP) Reports Better-Than-Expected Q3 Loss of $0.22
More News related to CHTP
- Results From Chelsea Therapeutics' Phase III Trial of Droxidopa in Neurogenic Orthostatic Hypotension to be Presented at 20th Annual International Symposium on the Autonomic Nervous System
- Unusual 11 Mid-Day Movers 11/03: LNY, BNI, DDRX, BDK Higher; CKEC, TPGI, CHTP, CMLS Lower
- Morning Movers 10/03: BNI, DDRX, BDK, AIMC, RTEC, MEDW Higher; CKEC, TPGI, IBCP, NSTC, CMLS, HEB Lower
- After-Hours Movers 11/02: BDK, DDRX, ATSI, HLF, HTCH, SNCR, CAR Higher; TNS, HIMX, SVR, TXRH Lower
- Chelsea Therapeutics (CHTP) Reports Better-Than-Expected Q3 Loss of $0.22
Chelsea Therapeutics (NASDAQ: CHTP) reports Q3 loss of $0.22, 6 cents better than the analyst estimate of ($0.28).
Related Categories
EarningsStocks Mentioned
-0.04Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
